Subscribe to RSS
Case Report: Persistent Acromegaly – Effective Therapy with Lanreotide and Weekly Pegvisomant Injections
received 23 March 2018
revised 30 April 2018
accepted 09 May 2018
11 June 2018 (online)
Objective Therapeutic options for persistent acromegaly after surgery include another surgical approach, radiotherapy, medical therapy or a combination of these procedures. We describe a patient with persistent acromegaly despite heavy pre-treatment who was in need of a simplified mode of effective therapy.
Methods In a 45-year old patient after transsphenoidal pituitary surgery followed by linear accelerator irradiation of the residual tumor two years later acromegaly could not be controlled by a tolerable dosage of intramuscular octreotide LAR. For professional reasons the patient requested a simplified mode of treatment.
Results In order to improve efficacy and treatment convenience, we combined subcutaneous injections of lanreotide up to 120 mg monthly performed by the patient’s spouse and of pegvisomant 80 mg weekly conducted by the patient himself. This therapy was well tolerated and satisfactory endocrine control was achieved. Magnetic resonance imaging did not show any remaining tumor within a year. 5 years following surgery and 3 years following irradiation pegvisomant could be stopped and levels of insulin growth factor 1 and growth hormone remained in the normal range. The interval of lanreotide given subcutaneously by the patient’s spouse could be extended stepwise and somatostatin analog treatment was terminated after 7.5 years when the patient was cured.
Conclusions Excessive growth hormone secretion persisting after pituitary surgery and irradiation can be controlled in a convenient way for the patient with acromegaly by combining monthly lanreotide and weekly pegvisomant injections, if monotherapy with a somatostatin analog fails.
- 1 Feelders RA, Hofland LJ, van Aken MO. et al. Medical therapy of acromegaly: Efficacy and safety of somatostatin analogues. Drugs 2009; 69: 2207-2226
- 2 Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S. et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: A systematic review and meta-analysis. PLoS One 2013; 8: e61523
- 3 Andersen M. Management of endocrine disease: GH excess: Diagnosis and medical therapy. Eur J Endocrinol 2014; 170: R31-R41
- 4 Katznelson L, Laws Jr. ER, Melmed S. et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
- 5 Fleseriu M. The role of combination medical therapy in acromegaly: Hope for the nonresponsive patient. Curr Opin Endocrinol Diabetes Obes 2013; 20: 321-329
- 6 Wang JW, Li Y, Mao ZG. et al. Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas. Patient Prefer Adherence 2014; 8: 43-51
- 7 van der Lely AJ, Bernabeu I, Cap J. et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011; 164: 325-333
- 8 Neggers SJ, van Aken MO, de Herder WW. et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008; 93: 3853-3859
- 9 Neggers SJ, de Herder WW, Janssen JA. et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: Long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009; 160: 529-533
- 10 Bevan JS, Newell-Price J, Wass JA. et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 2008; 68: 343-349
- 11 Salvatori R, Nachtigall LB, Cook DM. et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 2010; 13: 115-122
- 12 Salvatori R, Woodmansee WW, Molitch M. et al. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 2014; 17: 13-21
- 13 Schopohl J, Strasburger CJ, Caird D. et al. Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011; 119: 156-162
- 14 Adelman DT, Liebert KJ, Nachtigall LB. et al. Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med 2013; 6: 31-38
- 15 Neggers SJ, van Aken MO, Janssen JA et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007
- 16 Puig-Domingo M, Soto A, Venegas E. et al. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. Endocrinol Nutr 2016; 63: 397-408
- 17 van der Lely AJ, Muller A, Janssen JA. et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001; 86: 478-481
- 18 Higham CE, Thomas JD, Bidlingmaier M. et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 2009; 161: 21-25
- 19 Neggers SJ, de Herder WW, Feelders RA. et al. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011; 14: 253-258